[SARS-CoV-2 antibodies after booster vaccination. Identification of subgroups with poor response]. / Anticuerpos contra el SARS-CoV-2 tras la dosis de vacuna de recuerdo. Identificación de subgrupos con respuesta insuficiente.

Objective: To determine which patients within the high-risk group are most likely to have insufficient post-vaccination immunity. Methods: Determination of IgG titers against SARS-CoV-2 after the booster dose. Vaccine response was categorized as negative (IgG titers < 34 BAU/ml), indeterminate (titers 34 - 259 BAU/ml) or positive (≥ 260 BAU/ml). Results: 765 patients were included (31.25% of those vaccinated). 54 (7.1%) on treatment with biologics, 90 (11.8%) with hematologic disease, 299 (39.1%) with oncologic pathology, 304 (39.7%) with solid organ transplant and 18 (2.4%) with immunosuppression for other reasons. 74 patients (9.7%) had negative serology and 45 (5.9%) had indeterminate titers. By diagnostic group, the patients with the highest proportion of negative or indeterminate serology were patients with biologic treatment (55.6%, mainly at expense of antiCD20), hematologic (35.4%) and transplant patients (17.8%, mainly lung and kidney). Oncology and other immunosuppressed patients had a favorable response to vaccination. Conclusion: Patients treated with antiCD20 drugs, hematologic patients and transplanted patients (mainly lung and kidney) have a higher risk of not achieving post-vaccination immunity. It is essential to identify them in order to individualize and optimize their management.

SARS-COV-2 antibodies after booster vaccination. Identification of subgroups with poor response Anticuerpos contra el SARS-COV-2 tras la dosis de vacuna de recuerdo. Identificación de subgrupos con respuesta insuficiente

Objective To determine which patients within the high-risk group are most likely to have insufficient post-vaccination immunity. Methods Determination of IgG titers against SARS-CoV-2 after the booster dose. Vaccine response was categorized as negative (IgG titers < 34 BAU/ml), indeterminate (titers 34–259 BAU/ml) or positive (≥260 BAU/ml). Results 765 patients were included (31.25% of those vaccinated). 54 (7.1%) on treatment with biologics, 90 (11.8%) with hematologic disease, 299 (39.1%) with oncologic pathology, 304 (39.7%) with solid organ transplant and 18 (2.4%) with immunosuppression for other reasons. 74 patients (9.7%) had negative serology and 45 (5.9%) had indeterminate titers. By diagnostic group, the patients with the highest proportion of negative or indeterminate serology were patients with biologic treatment (55.6%, mainly at expense of antiCD20), hematologic (35.4%) and transplant patients (17.8%, mainly lung and kidney). Oncology and other immunosuppressed patients had a favorable response to vaccination. Conclusion Patients treated with antiCD20 drugs, hematologic patients and transplanted patients (mainly lung and kidney) have a higher risk of not achieving post-vaccination immunity. It is essential to identify them in order to individualize and optimize their management.

SARS-COV-2 antibodies after booster vaccination. Identification of subgroups with poor response.

OBJECTIVE: To determine which patients within the high-risk group are most likely to have insufficient post-vaccination immunity. METHODS: Determination of IgG titers against SARS-CoV-2 after the booster dose. Vaccine response was categorized as negative (IgG titers < 34 BAU/ml), indeterminate (titers 34-259 BAU/ml) or positive (≥260 BAU/ml). RESULTS: 765 patients were included (31.25% of those vaccinated). 54 (7.1%) on treatment with biologics, 90 (11.8%) with hematologic disease, 299 (39.1%) with oncologic pathology, 304 (39.7%) with solid organ transplant and 18 (2.4%) with immunosuppression for other reasons. 74 patients (9.7%) had negative serology and 45 (5.9%) had indeterminate titers. By diagnostic group, the patients with the highest proportion of negative or indeterminate serology were patients with biologic treatment (55.6%, mainly at expense of antiCD20), hematologic (35.4%) and transplant patients (17.8%, mainly lung and kidney). Oncology and other immunosuppressed patients had a favorable response to vaccination. CONCLUSION: Patients treated with antiCD20 drugs, hematologic patients and transplanted patients (mainly lung and kidney) have a higher risk of not achieving post-vaccination immunity. It is essential to identify them in order to individualize and optimize their management.

Description of the first case of SARS-CoV-2 reinfection in Galicia (Spain)

This study presents the first confirmed case of SARS-CoV-2 reinfection in Galicia, Spain, and a summary of the data on the first reinfections studied in the autonomous community. The first patient with a confirmed reinfection, aged 69, started clinical COVID-19 on 28/03/2020 with coughing and asthenia and oxygen saturation of 97%-98%.98%. He then complained of persistent weariness for several months. The clinical episode occurred while in quarantine on 03 March 2022 due to intimate interaction with her cohabitating daughter and a positive COVID-19 (secondary attack rate of 33%). The first positive result was achieved on 03 March 2020 (E gene CT<30, RdRP/S gene CT<30, N gene CT<30). Noserological study was done, and the patient was discharged on 04 March 2020 according to epidemiological guidelines. On 9 January 2021 he presented a second COVID-19 case after 289 days. In this second episode, the patient developed cough and general malaise on 09/01/2021 and was PCR positive on the same day (E gene CT<30, RdRP genes <30%). In both cases, the patient progressed well and did not require hospitalization. Between 1 April 2021, and 10 March 2021, there were 485 re-infections recorded in the Autonomous Community of Galicia, with 245 occurring in the province of A Corua (51%), 68 in Lugo (14%), 37 in Ourense (8%) and 135 in Pontevedra (28%). Because reinfection features and patterns may change, information must be collected throughout the pandemic.

Description of the first case of SARS-CoV-2 reinfection in Galicia (Spain)

Since the first reinfection by SARS-CoV-2 was known in August 2020, several cases have been described around the world. We present the first reinfection of an immunocompetent patient confirmed in Galicia (Spain). The clinical-epidemiological information was obtained through an interview with the patient. The microbiological diagnosis was made by PCR of the nasopharyngeal exudate samples, and a serological study was carried out. In addition, a summary of the characteristics of all reinfections identified between 04-01-2021 and 03-10-2021 is presented. Desde que en Agosto de 2020 se conociese la primera reinfección por SARS-CoV-2, se han descrito varios casos en todo el Mundo. Presentamos el primer caso confirmado en Galicia (España) de reinfección, en una paciente inmunocompetente. La información clínico-epidemiológica se obtuvo mediante entrevista con la paciente. El diagnóstico microbiológico se realizó mediante PCR de las muestras de exudado nasofaríngeo y se realizó estudio serológico. Además, se presenta un resumen de las características de todas las reinfecciones identificadas entre el 04-01-2021 y el 03-10-2021.